United States · Investor

Rock Springs Capital

Last cheque observed Jun 2026; 36 cheques on record.

Deploying nowNew fund $1.1B, Jan 2026Hedge fund

GrowthSeedSeries AHealthcare

Deploying now
50%of best year1cheques in 12 months, 36 on record
Since the last cheque144days00hrs00min00sec
Median round$102MRounds led0 of 36Exits1 from the portfolioMostly inUnited States, 78%
Pitch Rock Springs Capital

Rock Springs Capital highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series B and Series C: 74% of its rounds

  3. 03

    1 exits from the portfolio

What they do

Rock Springs Capital is a specialist healthcare investment firm managing $1.8B across two strategies.From their own website
Type
Hedge fund (from a list, unverified)
Cheque size
Not stated
Stages
GrowthSeedSeries A
Sectors
Healthcare
Based in
Baltimore, United States
Cold pitches
Not accepted

The record

Every round we can evidence, newest first36 appearances

  1. 2026

    1 round

  2. Jun
    City TherapeuticsSeries B · US · Ventureburn$100MWith 8 others
  3. 2024

    2 rounds

  4. May
    Zenas BioPharmaSeries C · US · Tellus BioVentures$200MWith 14 others
  5. Jan
    Apollo TherapeuticsSeries C · GB · UCL Technology Fund$260MWith 2 others
  6. 2023

    1 round

  7. Feb
    Hemab TherapeuticsSeries B · DK · Firms' own news pages$135MWith 8 others
  8. 2021

    2 rounds

  9. Aug
    Vigil NeuroscienceSeries B · US · Hatteras Venture Partners$90MWith 12 others
  10. Jun
    Apollo TherapeuticsSeries A · GB · UCL Technology Fund$140MWith 3 others
  11. 2020

    1 round

  12. Mar
    Kymera TherapeuticsSeries C · US · Hatteras Venture Partners$102MWith 7 others
  13. 2019

    1 round

  14. Dec
    Imperative CareSeries C · US · FinSMEs$85MWith 5 others
  15. 2016

    1 round

  16. Jun
    Vedanta BiosciencesUS · Xconomy$50MWith 2 others
  17. 2015

    15 rounds

  18. Dec
    Clearside BiomedicalSeries C · US$20MWith 3 others
  19. Nov
    ObsEvaSeries B · CH$60MWith 4 others
  20. Oct
    Audentes TherapeuticsSeries C · US$65MWith 11 others
  21. Sept
    Aclaris TherapeuticsSeries C · US$40MWith 8 others
  22. Sept
    Proteostasis TherapeuticsSeries B · US$37MWith 7 others
  23. Sept
    AveXisSeries D · US$65MWith 11 others
  24. Jul
    Ra PharmaceuticalsSeries B · US$59MWith 8 others
  25. Jun
    Clementia PharmaceuticalsSeries B · CA$60MWith 6 others
  26. May
    BeiGeneSeries B · CN$97MWith 3 others
  27. May
    Adaptive BiotechnologiesSeries F · US$195MWith 3 others
  28. Apr
    MerusSeries C · NL$79MWith 10 others
  29. Apr
    Dimension TherapeuticsSeries B · US$65MWith 7 others
  30. Mar
    Collegium PharmaceuticalVenture · US$50MWith 10 others
  31. Mar
    Mersana TherapeuticsSeries B · US$35MWith 4 others
  32. Feb
    Cidara TherapeuticsSeries B · US$42MWith 9 others
  33. 2014

    10 rounds

  34. Dec
    3-V BiosciencesSeries D · US$29MWith 3 others
  35. Dec
    Ascendis PharmaSeries D · US$60MWith 5 others
  36. Nov
    Nivalis TherapeuticsSeries B · US$30MWith 4 others
  37. Oct
    InvitaeSeries F · US$120MWith 13 others
  38. Sept
    AdaptimmuneSeries A · GB$104MWith 12 others
  39. Aug
    Civitas TherapeuticsSeries C · US$55MWith 11 others
  40. Aug
    DermiraSeries C · US$51MWith 7 others
  41. May
    Spark TherapeuticsSeries B · US$73MWith 5 others
  42. May
    Coherus BiosciencesSeries C · US$55MWith 9 others
  43. Apr
    Avalanche BiotechSeries B · US$55MWith 5 others
  44. 2013

    1 round

  45. Nov
    TriVascularSeries E · US · sec.gov$40MWith 8 others
  46. 2012

    1 round

  47. Nov
    Mirna TherapeuticsSeries D · US · sec.gov$17MWith 10 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration5 named

AHAidan Hugh O'ConnorChief Compliance Officer and General CounseliForm ADV
GMGordon Margraf ("mark") BussardMember/Limited PartneriForm ADV
GMGraham Margraff (Mark) McPhailMember/Limited PartneriForm ADV
KHKris Harlan JennerMember/Limited PartneriForm ADV
NCNnamdi C EtohChief Financial OfficeriForm ADV

We also hold 12 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$2.4Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
ROCK Springs Capital Management LP
SEC number
CRD 168648

Funds on its Form ADV

2 private funds, $5.8B in gross assets · filed Mar 2024

  1. Rock Springs Capital Master Fund L.P.Hedge635 investors$5.5B
  2. FOUR Pines Master Fund L.P.Hedge25 investors$264M

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

Civitas TherapeuticsBought by Acorda Therapeutics$525MSept 2014

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Rock Springs Capital. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Rock Springs Capital put money into.

Quick answers about Rock Springs Capital

What does Rock Springs Capital invest in?

Rock Springs Capital invests most often at Series B and Series C (74% of the rounds on record), in sectors such as Healthcare.

How active is Rock Springs Capital?

36 investments on record, 1 of them in the last 12 months. The most recent was in Jun 2026.

What has Rock Springs Capital invested in recently?

Its most recent investments on record: City Therapeutics (Series B, Jun 2026), Zenas BioPharma (Series C, May 2024) and Apollo Therapeutics (Series C, Jan 2024).

How big are Rock Springs Capital's cheques?

The median round it joins is $102M.

Does Rock Springs Capital lead rounds?

Rarely, if at all: none of its 36 investments on record names it as the lead.

Where does Rock Springs Capital invest?

Most of the companies it backs are in the United States (78%) and the United Kingdom (8%).

Is Rock Springs Capital investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

Who does Rock Springs Capital invest alongside?

Most often RA Capital Management (13 rounds together), New Enterprise Associates (11 rounds together) and OrbiMed (9 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it